HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Lisata Therapeutics (NASDAQ:LSTA) and maintained a price target of $15.
May 21, 2024 | 10:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Lisata Therapeutics and maintained a price target of $15, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a maintained price target of $15 by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in Lisata Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100